Program
cemsidomide
Also written as “Cemsidomide”.
Its studies are mostly in Multiple Myeloma, led by C4 Therapeutics.
Furthest: phase 2, since Dec 9, 20253 company-led studies, 3 open or runningNext primary completion: Dec 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| C4 Therapeutics | 33 open or running | phase 2since Dec 9, 2025 | Feb 12, 2021 | Dec 2028phase 1 · NCT07280013 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 12, 2021First study: phase 1 study in Multiple MyelomaFirst studyNCT04756726 · 224 enrolled · United States
- Dec 1, 2025Phase 1 study in Multiple MyelomaNCT07280013 · 60 planned · United States
- Dec 9, 2025Phase 2 study in Multiple MyelomaPhase 2 reachedNCT07284758 · 100 planned · United States, France, Italy and more
Ahead
- Dec 2028Primary completion: phase 1 study in Multiple MyelomaNCT07280013
- Mar 2030Primary completion: phase 2 study in Multiple MyelomaNCT07284758
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07284758Multiple Myeloma · United States, France, Italy and more | 2 | Recruiting | Mar 2030 | 100 |
| NCT07280013Multiple Myeloma · United States | 1 | Recruiting | Dec 2028 | 60 |
| NCT04756726Multiple Myeloma · United States | 1 | Active, not recruiting | Sep 30, 2026 | 224 |
How it is read
Names in the registry
- “Cemsidomide”, 2 entries
- “cemsidomide”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.